News Sentiment

CTNM sentiment intelligence

Contineum Therapeutics, Inc. Class A Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 15.19 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

85/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend active

+0.6% over one week, +27.9% over four weeks, trend active, and near fair-value range.

Latest direct headline Positive

Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?

Market Reaction

Balanced read

51/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 85/100 classification
One-week reaction 0.6% Price digesting
Trend fit Trend active 27.9% over four weeks
Fair value 23.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 41
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 15
Market source 8
Investing.com 4
TradingView 4
The Globe and Mail 2
Investing.com Canada 2
Investing.com Nigeria 2
Business Wire 2

Event Lens

What the news is about

Classified themes
Market update 41
Earnings 17
Analyst action 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 60
Stock Titan Direct company coverage

Contineum Therapeutics (CTNM) elects Class II directors, ratifies Ernst & Young as 2026 auditor

Contineum Therapeutics, Inc. (CTNM) held its 2026 Annual Meeting of Stockholders on June 26, 2026. During the meeting, stockholders elected three Class II directors—Evert Schimmelpennink, Lori M. Lyons-Williams, and Diego Miralles, M.D.—to serve until the 2029 annual meeting. Add

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 20:39
Source
Stock Titan
The Globe and Mail Direct company coverage

Contineum Stockholders Hold 2026 Virtual Annual Meeting

Contineum Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders virtually on June 26, 2026. Stockholders re-elected three Class II directors and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026. Anal

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 13:39
Source
The Globe and Mail
TradingView Direct company coverage

Contineum Therapeutics, Inc. Class A Actuals & Estimates (NASDAQ:CTNM)

This article provides an overview of Contineum Therapeutics, Inc. (NASDAQ: CTNM) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details financial estimates like earnings per share and revenue, and notes that the c

Tone
Positive 71/100
Event
Earnings
Published
26 Jun 2026 08:10
Source
TradingView